Drug Trial Radar · NCT07765446
Study of SIR2501 in Solid Tumor Patients Receiving Paclitaxel
Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
Aug 21, 2026
Primary completion
Dec 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Sironax USA, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 2, open-label study will evaluate the safety, tolerability, and pharmacokinetics of SIR2501 in adults with solid tumors who are scheduled to receive paclitaxel-based chemotherapy. The study will also explore whether SIR2501 has the potential to reduce the development of chemotherapy-induced peripheral neuropathy (CIPN).
Conditions
- Chemotherapy-induced Peripheral Neuropathy
Interventions
SIR2501Drug
Experimental: 30 mg SIR2501 administered at 30 mg dose level. Experimental: 45 mg SIR2501 administered at 45 mg dose level. Experimental: 60 mg SIR2501 administered at 60 mg dose level.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary OutcomeTime frame: From first dose through 1 month after last dose
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Hollywood, Florida · Recruiting
Site not named
Baltimore, Maryland · Recruiting
Site not named
Boston, Massachusetts · Not yet recruiting
Site not named
East Brunswick, New Jersey · Recruiting
Site not named
Winston-Salem, North Carolina · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.